Table 2.
Indirectly related awards to the development of sofosbuvir
| Project Title | Agency | Project number | Contact principle investigator | Organization name | Fiscal year | Fiscal year total cost | 2018 US% |
|---|---|---|---|---|---|---|---|
| Synthesis and Biotransformation of Anti-HIV Prodrugs | NIAID | 5R01AI025899-07 | Chung K. Chu | University of Georgia | 1993 | US$252 551 | US$438 874 |
| 2R01AI025899-08 | 1994 | US$218 198 | US$369 710 | ||||
| 5R01AI025899-09 | 1995 | US$249 344 | US$410 840 | ||||
| 5R01AI025899-10 | 1996 | US$235 986 | US$377 678 | ||||
| 3R01AI025899-10S1 | 1996 | US$24 507 | US$39 222 | ||||
| 5R01AI025899-11 | 1997 | US$272 387 | US$426 158 | ||||
| 3R01AI025899-11S1 | 1998 | US$75 450 | US$116 233 | ||||
| 2R01AI025899-12 | 1998 | US$253 895 | US$391 134 | ||||
| 5R01AI025899-13 | 1999 | US$343 217 | US$517 312 | ||||
| 5R01AI025899-14 | 2000 | US$353 514 | US$515 504 | ||||
| 2R37AI025899-15A1 | 2001 | US$366 482 | US$519 628 | ||||
| 5R37AI025899-16 | 2002 | US$371 422 | US$518 436 | ||||
| 5R37AI025899-17 | 2003 | US$382 566 | US$522 092 | ||||
| 5R37AI025899-18 | 2004 | US$394 042 | US$523 805 | ||||
| 5R37AI025899-19 | 2005 | US$405 867 | US$521 844 | ||||
| 4R37AI025899-20 | 2006 | US$503 323 | US$626 924 | ||||
| 5R37AI025899-21 | 2007 | US$491 584 | US$595 466 | ||||
| Synthesis and (Biological) Evaluation of Anti-HIV Nucleosides | NIAID | 5R01AI032351-02 | Chung K. Chu | University of Georgia | 1993 | US$173 665 | US$301 789 |
| 5R01AI032351-03 | 1994 | US$181 600 | US$307 699 | ||||
| 5R01AI032351-04 | 1995 | US$187 724 | US$309 310 | ||||
| 2R01AI032351-05 | 1996 | US$191 374 | US$306 260 | ||||
| 5R01AI032351-06 | 1997 | US$184 769 | US$289 077 | ||||
| 5R01AI032351-07 | 1998 | US$275 462 | US$424 359 | ||||
| 2R01AI032351-08A1 | 1999 | US$239 594 | US$361 127 | ||||
| 5R01AI032351-09 | 2000 | US$234 898 | US$342 535 | ||||
| 5R01AI032351-10 | 2001 | US$241 696 | US$342 697 | ||||
| 2R01AI032351-11 | 2002 | US$306 294 | US$427 530 | ||||
| 5R01AI032351-12 | 2003 | US$303 947 | US$414 800 | ||||
| 5R01AI032351-13 | 2004 | US$313 063 | US$416 158 | ||||
| 5R01AI032351-14 | 2005 | US$322 455 | US$414 597 | ||||
| Proteolytic Control of Flavivirus Replication | NIAID | 5R01AI031501-03 | Charles Rice | Washington University | 1993 | US$178 820 | US$310 747 |
| 5R01AI031501-04 | 1994 | US$178 334 | US$302 165 | ||||
| 5R01AI031501-05 | 1995 | US$185 368 | US$305 427 | ||||
| Hepatitis C Virus-Developing Antivirals and Vaccines | NCI | 5R01CA057973-02 | Charles Rice | Washington University | 1993 | US$273 694 | US$475 615 |
| 5R01CA057973-03 | 1994 | US$278 900 | US$472 562 | ||||
| 5R01CA057973-04 | 1995 | US$297 719 | US$490 546 | ||||
| 2R01CA057973-05 | 1996 | US$270 224 | US$432 473 | ||||
| 5R01CA057973-06 | 1997 | US$323 448 | US$506 044 | ||||
| 5R01CA057973-07 | 1998 | US$303 203 | US$467 094 | ||||
| 5R01CA057973-08 | 1999 | US$314 595 | US$474 171 | ||||
| 5R01CA057973-09 | 2000 | US$262 940 | US$383 426 | ||||
| 7R01CA057973-10 | Rockefeller University | 2000 | US$63 500 | US$92 597 | |||
| 2R01CA057973-11 | 2003 | US$385 488 | US$526 080 | ||||
| 5R01CA057973-12 | 2004 | US$395 975 | US$526 374 | ||||
| 5R01CA057973-13 | 2005 | US$396 857 | US$510 258 | ||||
| 5R01CA057973-14 | 2006 | US$387 818 | US$483 054 | ||||
| 5R01CA057973-15 | 2007 | US$376 571 | US$456 149 | ||||
| Pathogenesis of Liver Disease in Hepatitis | NIAID | 2R01AI020001-10 | Francis Vincent Chisari | Scripps Research Institute | 1993 | US$377 751 | US$656 442 |
| 5R01AI020001-11 | 1994 | US$387 918 | US$657 280 | ||||
| 5R01AI020001-12 | 1995 | US$389 046 | US$641 025 | ||||
| 5R01AI020001-13 | 1996 | US$411 437 | US$658 475 | ||||
| 5R01AI020001-14 | 1997 | US$430 173 | US$673 018 | ||||
| 2R01AI020001-15 | 1998 | US$466 772 | US$719 078 | ||||
| 5R01AI020001-16 | 1999 | US$427 991 | US$645 087 | ||||
| 5R01AI020001-17 | 2000 | US$459 678 | US$670 316 | ||||
| 5R01AI020001-18 | 2001 | US$471 489 | US$668 516 | ||||
| 5R01AI020001-19 | 2002 | US$511 845 | US$714 441 | ||||
| 2R01AI020001-20 | 2003 | US$320 175 | US$436 947 | ||||
| 5R01AI020001-21 | 2004 | US$556 979 | US$740 399 | ||||
| 5R01AI020001-22 | 2005 | US$570 762 | US$733 857 | ||||
| 5R01AI020001-23 | 2006 | US$571 211 | US$711 484 | ||||
| 5R01AI020001-24 | 2007 | US$568 508 | US$688 646 | ||||
| Hepatitis C Virus Disease Pathogenesis (in Pathogenic Mice) | NCI | 5R01CA058000-02 | Claudio Pasquinelli | Scripps Research Institute | 1993 | US$218 762 | US$380 157 |
| 5R01CA058000-03 | 1994 | US$223 753 | US$379 122 | ||||
| 5R01CA058000-04 | 1995 | US$232 801 | US$383 582 | ||||
| Hepatitis C Virus Immunobiology and Pathogenesis | NCI | 1R01CA076403-01 | Francis Vincent Chisari | Scripps Research Institute | 1998 | US$374 924 | US$577 583 |
| 5R01CA076403-02 | 1999 | US$318 343 | US$479 821 | ||||
| 5R01CA076403-03 | 2000 | US$417 683 | US$609 077 | ||||
| 5R01CA076403-04 | 2001 | US$429 161 | US$608 450 | ||||
| 5R01CA076403-05 | 2002 | US$466 687 | US$651 408 | ||||
| 2R01CA076403-06A1 | 2003 | US$518 621 | US$707 768 | ||||
| 5R01CA076403-07 | 2004 | US$531 431 | US$706 438 | ||||
| 5R01CA076403-08 | 2005 | US$544 625 | US$700 252 | ||||
| 5R01CA076403-09 | 2006 | US$545 094 | US$678 953 | ||||
| 5R01CA076403-10 | 2007 | US$542 558 | US$657 212 | ||||
| Modified Purine Nucleosides as Antiviral Agents | NIAID | 1R43AI040775-01 | Phillip Furman | Triangle Pharmaceuticals | 1997 | US$85 163 | US$133 240 |
| Hepatitis C: Studies of Immunity and Pathogenesis | NIAID | 7U19AI040034-06 | Charles Rice | Rockefeller University | 2000 | US$680 907 | US$992 910 |
| 5U19AI040034-07 | 2001 | US$762 360 | US$1 080 936 | ||||
| 5U19AI040034-08 | 2002 | US$701 031 | US$978 509 | ||||
| 5U19AI040034-09 | 2003 | US$759 817 | US$1 036 931 | ||||
| 5U19AI040034-10 | 2004 | US$777 103 | US$1 033 012 | ||||
| 2U19AI040034-11 | 2005 | US$848 905 | US$1 091 480 | ||||
| 5U19AI040034-12 | 2006 | US$789 280 | US$983 103 | ||||
| 5U19AI040034-13 | 2007 | US$789 384 | US$956 198 | ||||
| Antiviral Screening Assays Based on HCV Replications | NIAID | 1R43AI049604-01 | Paul David Olivo | Apath LLC | 2001 | US$99 395 | US$140 930 |
| 2R44AI049604-02 | 2002 | US$429 325 | US$599 258 | ||||
| 5R44AI049604-03 | 2003 | US$320 675 | US$437 629 | ||||
| Characterization of the Hepatitis C NS5a Kinase Complex | NIAID | 1F32AI051820-01 | Timothy L. Tellinghuisen | Rockefeller University | 2002 | US$38 320 | US$53 487 |
| 5F32AI051820-02 | 2003 | US$46 420 | US$63 349 | ||||
| 5F32AI051820-03 | 2004 | US$48 928 | US$65 040 | ||||
| Immune Complexes: Origin and Effects in HCV Infection | NIAID | 1R01AI060561-01 | Lynn Dustin | Rockefeller University | 2003 | US$138 133 | US$188 511 |
| 5R01AI060561-02 | 2004 | US$421 250 | US$559 972 | ||||
| 5R01AI060561-03 | 2005 | US$421 979 | US$542 559 | ||||
| 5R01AI060561-04 | 2006 | US$412 571 | US$513 886 | ||||
| 5R01AI060561-05 | 2007 | US$400 606 | US$485 262 | ||||
| Cellular Genes that Control HCV Replication | NCI | 1R01CA108304-01 | Francis Vincent Chisari | Scripps Research Institute | 2003 | US$362 469 | US$494 666 |
| 5R01CA108304-02 | 2004 | US$362 353 | US$481 680 | ||||
| 5R01CA108304-03 | 2005 | US$403 153 | US$518 354 | ||||
| 5R01CA108304-04 | 2006 | US$373 281 | US$464 948 | ||||
| 5R01CA108304-05 | 2007 | US$371 351 | US$449 826 | ||||
| Functional Analysis of Hepatitis C Virus Glycoproteins | NIAID | 1R01AI050798-01A1 | Jane A. McKeating | Rockefeller University | 2004 | US$337 000 | US$447 978 |
| 5R01AI050798-02 | 2005 | US$337 667 | US$434 155 | ||||
| Analysis of Hepatitis C Virus Tropism in the Liver | NIDDK | 1F32DK070497-01 | Andrew J. Syder | Rockefeller University | 2005 | US$48 296 | US$62 097 |
| 5F32DK070497-02 | 2006 | US$50 428 | US$62 812 | ||||
| 5F32DK070497-03 | 2007 | US$52 898 | US$64 077 | ||||
| Characterization of the HCV NS5A Protein | NIAID | 1K22AI067645-01 | Timothy L. Tellinghuisen | Scripps Research Institute | 2006 | US$157 840 | US$196 601 |
| 5K22AI067645-02 | 2007 | US$108 000 | US$130 823 | ||||
| Novel Role of NS2 in HCV Infection | NIAID | 1F32AI069693-01A1 | Cynthia de la Fuente | Rockefeller University | 2007 | US$46 826 | US$56 721 |
| Characterization of the HCV p7 Protein | NIDDK | 1F32DK081193-01A1 | Christopher T. Jones | Rockefeller University | 2007 | US$51 278 | US$62 114 |
| Identification and Characterization of Cellular Factors Involved in HCV Entry | NIAID | 1R01AI072613-01 | Charles Rice | Rockefeller University | 2007 | US$422 500 | US$511 783 |
| US$37 967 400 | US$53 213 251 | ||||||